ArticleJournal of orthopaedic surgery and research2026
Mesenchymal stem cell-derived miR-125b-1-3p-abundant exosomes alleviate osteoarthritis by modulating the KDM6B-H3K27me3-FOXM1 axis.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOsteoarthritis (OA) is a prevalent degenerative joint disorder characterized by the gradual deterioration of articular cartilage and the presence of inflammatory responses. In recent years, the use of exosomes (Exos) derived from bone marrow-derived mesenchymal stem cells (BMSCs) has emerged as a promising novel therapeutic approach for OA because of the role of these cells in tissue repair and immunomodulation. This study aimed to elucidate the functions and molecular mechanisms of miR-125b-1-3p, which is enriched in BMSC-Exos, in the progression of OA.
methodsAn in vitro OA model was constructed by exposing chondrocytes to IL-1β, followed by treatment with BMSC-Exos, to evaluate their protective effects. miRNA sequencing was performed to analyse the miRNA expression profile in BMSC-Exos, identifying miR-125b-1-3p as a pivotal molecule. Dual-luciferase reporter assays and chromatin immunoprecipitation quantitative PCR (ChIP‒qPCR) were used to further validate the target genes of miR-125b-1-3p and its downstream regulatory network. Additionally, a rat OA model was constructed, and the therapeutic effects of miR-125b-1-3p in BMSC-Exos were verified in vivo through safranin O staining, HE staining, and immunohistochemical analysis.
resultsMicroRNA (miRNA) sequencing revealed that compared with its expression in untreated normal chondrocytes, the expression of miR-125b-1-3p was significantly enriched in BMSC-Exos but downregulated in IL-1β-induced OA chondrocytes. Functional experiments demonstrated that BMSC-Exos delivered miR-125b-1-3p, which markedly enhanced chondrocyte anabolism and migration while inhibiting apoptosis, thereby alleviating OA progression. Mechanistic studies revealed that miR-125b-1-3p targeted the histone demethylase KDM6B, resulting in increased H3K27me3 enrichment at the FOXM1 promoter region and epigenetic suppression of FOXM1 expression, ultimately exerting chondroprotective effects.
conclusionThis study elucidates a novel molecular mechanism through which BMSC-Exos shuttle miR-125b-1-3p to alleviate OA by modulating the KDM6B/H3K27me3/FOXM1 signalling axis. These findings provide a theoretical rationale and identify promising therapeutic targets for the development of exosome-based therapeutic strategies against OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.